COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

200.48

Increased from previous period

OCF/share exceeds 1.5x the Medical - Pharmaceuticals median of 0.01. Joel Greenblatt would see if this strong cash generation is sustainable.

Free Cash Flow per Share

177.32

Increased from previous period

FCF/share of 177.32 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if small leftover cash can become a big advantage.

Capex-to-Operating Cash Flow

11.55%

Increased from previous period

Capex/OCF ratio of 11.55% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

2.87

Increased from previous period

Ratio above 1.5x Medical - Pharmaceuticals median of 0.93. Joel Greenblatt would see if robust OCF is a recurring trait.

Operating Cash Flow-to-Sales Ratio

14.74%

Increased from previous period

OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 2.00%. Joel Greenblatt would see a standout ability to convert sales to cash.

Select Chart Metric:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

200.48

Increased from previous period

OCF/share exceeds 1.5x the Medical - Pharmaceuticals median of 0.01. Joel Greenblatt would see if this strong cash generation is sustainable.

Free Cash Flow per Share

177.32

Increased from previous period

FCF/share of 177.32 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if small leftover cash can become a big advantage.

Capex-to-Operating Cash Flow

11.55%

Increased from previous period

Capex/OCF ratio of 11.55% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

2.87

Increased from previous period

Ratio above 1.5x Medical - Pharmaceuticals median of 0.93. Joel Greenblatt would see if robust OCF is a recurring trait.

Operating Cash Flow-to-Sales Ratio

14.74%

Increased from previous period

OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 2.00%. Joel Greenblatt would see a standout ability to convert sales to cash.

Select Chart Metric: